Errors in Table 2

• July 1, 2026

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b

• by Mark Lebwohl, Andrew Blauvelt, Cynthia E. Kartman, Cianna Leatherwood, Kenneth B. Gordon, Naveed Sattar, Luis Puig, Joseph F. Merola, Kimberly Siu, Rona Wang, Luna Sun, Ann Leung, Najwa Somani, Maria Jose Rueda, Anabela Cardoso, Mark C. Genovese, April W. Armstrong, Bruce Strober

• July 1, 2026

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review

• by Julia Alicja Lewandowska, Agnieszka Owczarczyk–Saczonek

• May 19, 2026

GRAPPA, EULAR Criteria May Identify Complex PsA

Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.

• by Andrea Surnit

• July 23, 2026

• 3 min